论文信息 - Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX). - 字舞流文

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

C. Lepage | J. Taieb | R. Coriat | D. Malka | J. Bachet | É. Terrebonne | M. Gouttebel | F. Khemissa | Y. Rinaldi | E. Barbier | L. Miglianico | K. Bouhier‐Leporrier | P. Texereau | Anne-Laure Pointet | A. Gratet | H. Laharie-Mineur | A. Bidault | F. Ghiringhelli